|
Adenocarcinoma Of Esophagus
|
0.400 |
Biomarker
|
disease |
BEFREE |
The evidence from this systematic review is suggestive of a role for p16 as an epigenetic biomarker for the progression of BO to OADC.
|
29961009 |
2018 |
|
Adenocarcinoma Of Esophagus
|
0.400 |
Biomarker
|
disease |
BEFREE |
Barrett's esophagus is thought to progress to esophageal adenocarcinoma (EAC) through a stepwise progression with loss of CDKN2A followed by TP53 inactivation and aneuploidy.
|
26192918 |
2015 |
|
Adenocarcinoma Of Esophagus
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This study provides the first evidence that germline variation at the CDKN2A locus may influence EA susceptibility.
|
25280564 |
2014 |
|
Adenocarcinoma Of Esophagus
|
0.400 |
Biomarker
|
disease |
CTD_human |
Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity.
|
23525077 |
2013 |
|
Adenocarcinoma Of Esophagus
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
These findings are consistent with the hypothesis on the role of the p16 mutations in early phase of Barrett's epithelium progression to ADC.
|
22440936 |
2012 |
|
Adenocarcinoma Of Esophagus
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
Therefore, we examined whether acid increases methylation of p16 gene promoter and whether NADPH oxidase NOX5-S mediates acid-induced p16 hypermethylation in a Barrett's cell line BAR-T and an EA cell line OE33.
|
20576920 |
2010 |
|
Adenocarcinoma Of Esophagus
|
0.400 |
Biomarker
|
disease |
BEFREE |
The results suggest that silencing of ARF is involved in the pathogenesis of oesophageal adenocarcinoma and show that either DNA or histone methylation can provide the primary mechanism for ARF gene silencing.
|
18410530 |
2009 |
|
Adenocarcinoma Of Esophagus
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We have determined the p16 mutation spectrum for a cohort of 304 patients with Barrett's esophagus, a premalignant condition that predisposes to the development of esophageal adenocarcinoma.
|
19043591 |
2008 |
|
Adenocarcinoma Of Esophagus
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Abnormal p16 expression (negative, cytoplasmic, or combined cytoplasmic and nuclear staining) was present in all categories, rising from 68% in BE without dysplasia to 100% in AdenoCa, with cytoplasmic staining only showing a significant correlation with the severity of dysplasia.
|
18665038 |
2008 |
|
Adenocarcinoma Of Esophagus
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
At 10 y, all abnormalities, except CDKN2A mutation and methylation, contributed to EA risk significantly by univariate analysis, ranging from 17p LOH (relative risk [RR] = 10.6; 95% confidence interval [CI] 5.2-21.3, p < 0.001) to 9p LOH (RR = 2.6; 95% CI 1.1-6.0, p = 0.03).
|
17326708 |
2007 |
|
Adenocarcinoma Of Esophagus
|
0.400 |
Biomarker
|
disease |
BEFREE |
There were 7 cases of esophageal adenocarcinoma with loss of both MTAP and p16 for which precursor lesions were available.
|
16224217 |
2005 |
|
Adenocarcinoma Of Esophagus
|
0.400 |
Biomarker
|
disease |
BEFREE |
Allelic deletions of p53, p16 and Rb are common in oesophageal adenocarcinoma, and may be important in the development of this disease.
|
9542513 |
1998 |
|
Adenocarcinoma Of Esophagus
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
To determine whether p16 promoter hypermethylation may be an alternative mechanism for p16 inactivation in esophageal adenocarcinomas, we examined the methylation status of the p16 promoter in flow-sorted aneuploid cell populations from 21 patients with premalignant Barrett's epithelium or esophageal adenocarcinoma.
|
9205067 |
1997 |
|
Adenocarcinoma Of Esophagus
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
High frequency of simultaneous loss of p16 and p16beta gene expression in squamous cell carcinoma of the esophagus but not in adenocarcinoma of the esophagus or stomach.
|
9333024 |
1997 |